FHTX - CIK 0001822462
The table below shows Foghorn Therapeutics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$86.10M | -$100.41M | -$118.11M | $193.61M | -$50.25M | -$31.29M |
| Capital expenditure | $50.00K | $906.00K | $1.22M | $1.21M | $3.31M | $16.18M |
| Investing cash flow | $112.04M | -$29.90M | $144.45M | -$244.32M | $36.17M | -$108.91M |
| Dividends paid | - | - | - | - | - |
Foghorn Therapeutics Inc. reported operating cash flow of -$86.10M for fiscal year 2025. That is up 14.2% from -$100.41M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$46.34M (FY 2019) to -$86.10M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.02M | $105.43M | $1.78M | $1.76M | $22.42M | $217.47M |